Cardiol Therapeutics Inc Class A stock has seen notable fluctuations as it navigates recent developments in its clinical trials and financing activities.
This week, Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a significant decline in its stock price, closing at C$1.88, down 4.93% for the day and 19.25% over the week. While the company has been active in advancing its clinical programs, the market response suggests a cautious sentiment from investors.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$234.52M
52W high
$3.23
52W low
$1.23
1W change
-19.25%
Beta
0.72
Analyst Price Targets
Based on analyst covering CRDL · as of Sep 17, 2026
Wall Street analysts forecast CRDL stock price to rise 354.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+354.5% Upside
Current Price
C$1.32
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
76.8%
Annualized
90-Day Vol
66.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.05 | C$1.57 – C$2.67 |
| 60 trading days | C$2.17 | C$1.49 – C$3.16 |
| 90 trading days | C$2.31 | C$1.46 – C$3.65 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the implications of the recent enrollment milestones in the MAVERIC trial and the financial maneuvers as they assess the potential for future growth amid current stock performance.
C$1.88 - Current Stock Price
The stock has seen a 36.72% decline over the past month, yet it remains up 41.91% year-to-date, reflecting a complex performance landscape.
Bull case
Analysts have an average target of C$6.00 for the stock, indicating a positive outlook. There’s optimism surrounding Cardiol's ongoing clinical trials and recent financing efforts, which may extend its cash runway and support its strategic initiatives.
Bear case
On the other hand, the stock's recent performance and negative profit margins raise concerns about its sustainability, especially given the volatility in the market and competition in the healthcare sector.
Recent Price Action
Advertisement
Cardiol Therapeutics Inc Class A's stock closed at C$1.88, reflecting a decline of 4.93% for the day and a more substantial drop of 19.25% over the week. Year-to-date, the stock is still up 41.91%, indicating some resilience despite recent pressures.
Company News and Developments
Recently, Cardiol Therapeutics achieved a significant milestone by meeting its Phase III MAVERIC trial enrollment target ahead of schedule, expanding to 150 patients to further assess the efficacy of CardiolRx™ in recurrent pericarditis. Additionally, the company raised over USD $7 million from warrant exercises, extending its cash runway into the first half of 2028. This financing is crucial as it supports operations through the pivotal Phase III trial, which is key to the company's future prospects.
Technical Picture
From a technical perspective, Cardiol's stock is currently trading below its 50-day moving average of C$2.43, indicating a potential bearish trend. The 200-day moving average is slightly above the current price at C$1.78, suggesting a mixed outlook. The stock has a beta of 0.72, indicating lower volatility compared to the market. The 52-week range of C$1.23 to C$3.23 shows that the stock is currently at approximately 33% of its range, highlighting significant room for recovery or further decline.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
